The steroid 5-a reductase type 2 (SRD5A2) is critical for prostatic development and growth. Strategies to block SRD5A2 using 5-a reductase inhibitors (5ARI) remain a mainstay in the treatment of benign prostatic hyperplasia (BPH). However, one-third of men are resistant to 5ARI therapies. We previously have found that body mass index (BMI) can predict increased SRD5A2 promoter methylation level and decreased protein expression level. We have demonstrated that there is an androgenic to estrogenic switch when SRD5A2 is absent in the prostate gland. Here we wished to identify whether obesity-associated inflammation contributes to the androgenic to estrogenic switch in human prostate tissue.
INTRODUCTION AND OBJECTIVES:
The steroid 5-a reductase type 2 (SRD5A2) is critical for prostatic development and growth. Strategies to block SRD5A2 using 5-a reductase inhibitors (5ARI) remain a mainstay in the treatment of benign prostatic hyperplasia (BPH). However, one-third of men are resistant to 5ARI therapies. We previously have found that body mass index (BMI) can predict increased SRD5A2 promoter methylation level and decreased protein expression level. We have demonstrated that there is an androgenic to estrogenic switch when SRD5A2 is absent in the prostate gland. Here we wished to identify whether obesity-associated inflammation contributes to the androgenic to estrogenic switch in human prostate tissue.
METHODS: Human prostate tissue samples came from men undergoing transurethral prostate resection. Primary prostatic stromal cells were isolated from patients undergoing prostate reduction therapy for BPH. Adipocytes and macrophages were differentiated and treated with saturated fatty acids (SFA) to induce inflammation, and SFA-free conditioned media were collected for stromal cell culturing. Protein and mRNA were extracted from stromal cells, the expression of aromatase, estrogen receptor alpha (ERa), G-protein coupled estrogen receptor (GPER) and SRD5A2 was determined by Western Blot, ELISA and qPCR.
RESULTS: In BPH patients, BMI was significantly correlated with methylation of SRD5A2 gene promoter (p<0.05) and absence of SRD5A2 protein expression. Higher BMI was associated with higher SRD5A2 methylation levels and absence of SRD5A2 expression, as well as higher levels of aromatase and ERa (P<0.05, respectively). In primary cultured prostatic stromal cells, the levels of aromatase, ERa and GPER were significantly increased, the level of SRD5A2 was significantly decreased in a dose-dependent manner when cultured with conditioned media of adipocytes or macrophages. There were much higher levels of aromatase, ERa and GPER in the prostatic stromal cells when adipocytes and macrophages were pretreated with SFA. CONCLUSIONS: Our study demonstrates for the first time that there is an androgenic to estrogenic switch, which can improve SRD5A2 methylation level and reduce SRD5A2 expression in the prostate glands of overweight patients. Associated with body weight, somatic epigenetic silencing of SRD5A2 changes the prostatic hormonal milieu, and may modulate prostatic homeostasis and growth. Targeting the estrogenic signaling may serve as an effective treatment strategy in subset of overweight BPH patients. Central obesity is known to be involved in benign prostatic hyperplasia (BPH). Some study reports that increased fat tissue induces chronic intra-prostatic inflammation and the change of Estrogen Receptora(ERa) and ERb ratio which contributes to the development of BPH. We already confirmed that the high-fat-diet (HFD) induced obesity rats increased urinary frequency and the weight of prostate. Furthermore the ERa expression was significantly increased in the prostate of obesity rats. To find out the detailed mechanism of the ERs, the expression of the ERs and inflammatory cytokines in the prostate using a HFD induced obesity rat model were investigated.
METHODS: Male Wistar rats (8 weeks, n[16) were divided into four groups; normal diet group (ND, n[4), high fat diet group (HFD, n[4), high fat dietþERa antagonist (HFD-ERa antagonist, n[4), high fat dietþERb agonist (HFD-ERb agonist, n[4). The ND formula contained 5%fat, meanwhile the HFD contained 32% fat. The rats were maintained on these diets for 16 weeks. HFD-ERa antagonist and HFDERb agonist rats were administered since 12 week. ERa antagonist: MPP dihydrochloride 1mg/kg/day, ERb agonist: S-Equol 5mg/kg/day. We investigated the prostate weight, analysis of mRNA expression and histopathology of the prostate in each group.
RESULTS: In HFD, weight of the prostate and urinary frequency was significantly increased compared to ND. In addition, the mRNA expression of inflammatory cytokines (IL-1b, IL-6) were significantly increased. In HFD-ERa antagonist, weight of the prostate and urinary frequency was decreased compared to HFD. The mRNA expression of inflammatory cytokines were also significantly decreased compared to HFD. In Hematoxylin-Eosin stain and Masson Trichrome stain, inflammatory cells and collagen fibers were increased into prostatic stromal area in HFD, while ND and HFD-ERa antagonist did not demonstrate.
CONCLUSIONS: HFD intake induced prostatic enlargement and inflammation in associated with altered immune-balance and the expression of ERs. ERa antagonist could play the role of prevention to BPH associated with obesity.
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MP06-03 EFFECTS OF COX2 INHIBITION ON BLADDER OVERACTIVITY IN RAT MODEL OF CHEMICALLY INDUCED PROSTATIC INFLAMMATION
Shinsuke Mizoguchi*, Pittsburgh, PA; Kenichi Mori, Hiromitsu Mimata, Oita, Japan; Jianshu Ni, Masahiro Kurobe, Tetsuichi Saito, Donaldo B. DeFranco, Zhou Wang, Naoki Yoshimura, Pittsburgh, PA INTRODUCTION AND OBJECTIVES: There is increasing evidence that prostatic inflammation contributes to lower urinary tract symptoms (LUTS) in male with benign prostatic hyperplasia (BPH) and that cyclooxygenase-2 (COX-2) expression is increased in BPH tissues from patients exhibiting significant inflammation. Therefore, to reveal the role of COX-2-dependent prostatic inflammation in bladder overactivity, we investigated bladder function and molecular expressions in the prostate and pelvic afferent pathways after prostatic inflammation as well as the effects of COX-2 inhibition on bladder overactivity using a rat model. METHODS: Male SD rats at 8 weeks old were used. Prostatic inflammation was induced by 5% formalin injection into ventral lobes of the prostate and saline was injected in the control group (Sham). Rats with prostatic inflammation were divided into COX-2 inhibitor (celecoxib) therapy (Treatment) and placebo groups (Placebo). Rats were treated with celecoxib at a dose of 10mg/kg daily from 2 days before induction of prostatic inflammation. Twenty-eight days later, conscious cystometry was performed to assess bladder function. After cystometry, the prostate and L6-S1 dorsal root ganglia (DRG) were excised for analysis of mRNA expression levels of IL1b and COX-2 in the prostate and a Kþ channel a-subunit, Kv1.4, in DRG as well as histological evaluation of prostate and bladder.
RESULTS: In cystometry, intercontraction intervals (ICI) were significantly decreased in Placebo group compared to Sham group. mRNA expressions of IL1b and COX-2 in the prostate were significantly increased while mRNA expression of Kv1.4 in L6-S1 DRG was significantly decreased in Placebo group compared to Sham rats. However, these changes were normalized in Treatment group. Prostatic sections from Placebo group demonstrated infiltration of inflammatory cells, but not in Sham or Treatment group. There were no significant inflammatory changes in bladder sections from any groups.
CONCLUSIONS: COX-2 inhibition improved not only prostatic inflammation evidenced by decreases of upregulated IL1b and COX-2 levels, but also bladder overactivity as shown by shorter ICI in association with decreased Kv1.4 expression in pelvic afferent pathways. These results suggest that prostatic inflammation mediated by COX-2 plays an important role in bladder overactivity possibly induced by prostate-to-bladder cross-talk through pelvic afferent pathways. Thus, these COX-2-dependent mechanisms might contribute to male LUTS due to BPH associated with prostatic inflammation.
Source of Funding: NIH U54DK112079
MP06-04 INDUCIBLE PROSTATE LUMINAL EPITHELIAL CELL-SPECIFIC DELETION OF CDH1 INDUCES MURINE PROSTATIC HYPERPLASIA, INFLAMMATION, AND STROMAL FIBROSIS
Laura Pascal*, Shinsuke Mizoguchi, Rajiv Dhir, Wei Chen, Ke Wang, Joel Nelson, Pittsburgh, PA; Daniel Metzger, Pierre Chambon, Illkirch, France; Naoki Yoshimura, Zhou Wang, Pittsburgh, PA INTRODUCTION AND OBJECTIVES: Chronic inflammation is thought to contribute to the development of prostatitis and benign prostatic hyperplasia (BPH). In the prostate, the epithelial barrier functions to provide a selectively permeable barrier which serves as an interface between the glandular lumen and the underlying tissues. Ecadherin is an important adherens junction that helps to maintain the epithelial barrier in mucous membranes. This study explored the potential impact of reduced barrier function induced by deletion of Ecadherin in the murine prostate.
METHODS: The PSA-CreERT2 transgenic mouse strain expressing tamoxifen-inducible CreERT2 recombinase driven by a 6-kb human PSA promoter/enhancer was crossed with the B6.129-Cdh1tm2Kem/J mouse to generate bigenic PSA-CreERT2/Cdh1-/-mice. Deletion of E-cadherin was performed by transient administration of tamoxifen when mice reached sexual maturity (7 weeks of age). Void Spot Assays and cystometry were used to assess bladder function. Mice were examined histologically at 150 days and 365 days of age.
RESULTS: Mice with Cdh1 deletion had increased proliferation, inflammation, and stromal fibrosis at 150 days of age, as well as potential changes in bladder voiding. These alterations persisted at 365 days of age, suggesting that the loss of E-cadherin could contribute to the development of a chronically inflamed prostate.
CONCLUSIONS: These findings suggest that loss of epithelial barrier integrity in the prostate could result in chronic inflammation and the development of stromal fibrosis, inflammation and benign epithelial hyperplasia characteristic of BPH and prostatitis. However, its role has never been determined in the prostate. The current study aimed to elucidate the roles of IL-21R in the development of BPH.
METHODS: Human prostate tissues, cell lines and rats were used. The expression and localization of IL-21R were determined with quantitative real-time PCR (qRT-PCR), Western Blot, and immunohistochemistry staining. BPH-1 cells with IL-21R silenced were cultured or co-cultured with macrophages (active THP-1, AcTHP-1).
Apoptosis and cell cycles were tested with Flow Cytometry and Western Blot. Epithelial-mesenchymal transition (EMT) processes were detected with Western Blot and immunofluorescent staining. In vivo, rat prostatitis concomitant with BPH model was induced through intraprostatic injection of lipopolysaccharide (LPS). Rat prostate was observed with Hematoxylin and Eosin (H & E) staining and masson's trichrome staining. The expression and localization of IL-21R in rat prostate were also examined.
RESULTS: IL-21R was found to be highly expressed in human, as well as rat, prostate, mainly in the epithelial compartment. BPH concomitant with prostatitis significantly upregulated the expression of IL-21R. Knockdown of IL-21R induced cell apoptosis and cycle arrest at G0/G1 phase, and blocked EMT processes in BPH-1 cells. When IL-21R silenced BPH-1 cells were co-cultured with AcTHP-1 cells, these aforementioned processes and IL-21R were completely reversed. Prostatic hyperplasia was associated with IL-21R upregulation in the LPS induced prostatitic rat. CONCLUSIONS: Our novel data suggests modulated expression functional activity of IL-21R in the development of BPH. IL-21R mainly localized in prostate epithelium and it was upregulated in hyperplastic prostate tissues. IL-21R enhanced proliferation of BPH-1 cells, via inhibition of cell apoptosis and modulating cell cycles, as well as EMT processes in the case of inflammatory stimuli.
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